Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

Table 1

Phase III studies with bevacizumab and chemotherapy as first-line treatment of metastatic breast cancer.

Study	Treatment line	Arms	Patients	Response rate	Progression-free survival	Overall survival	Crossover
E2100; (2007)	First	Paclitaxel q1w +/− Bev 10 mg/kg q2w	722	36.9% versus 21.2% (𝑃<0.001)	11.8 versus 5.9 months [HR 0.6 (0.51–0.7)]	26.7 versus 25.2 months [HR 0.88 (𝑃=0.16)]	Not allowed
AVADO; (2008)	First	Docetaxel q3w + Bev 15 mg/kg or Bev 7.5 mg/kg or Placebo q3w	736	64% (𝑃<0.001) versus 55% (𝑃=0.07) versus 46%	10.1 [HR 0.77 (0.64–0.93)] versus 9.0 [HR 0.86 (0.72–1.04)] versus 8.2 months	30.2 [HR 1.03 (0.7–1.3)] versus 30.8 [HR 1.05 (0.81–1.36)] versus 31.9 months	Allowed
RIBBON 1; (2009)	First	Capecitabine q3w + Bev 15 mg/kg q3w or Placebo q3w; Anthracycline^1/ Taxane^2 q3w + Bev 15 mg/kg q3w or Placebo q3w	1,237	35.4% versus 23.6% (𝑃=0.009); 51.3% versus 37.9% (𝑃=0.005)	8.6 versus 5.7 months [HR 0.69 (0.56–0.84)]; 9.2 versus 8.0 months [HR 0.64 (0.52–0.80)]	29.0 versus 21.2 months [HR 0.85 (0.63–1.14)]; 25.2 versus 23.8 months [HR 1.03 (0.77–1.38)]	Allowed

¹Adriamycin or Epirubicin + Cyclophosphamide +/− 5-Fluorouracil q3w; ²Docetaxel or nab-Paclitaxel q3w.
Abbreviations: ORR: overall response rate; PFS: progression-free survival; HR: hazard ratio; LD: low dose; HD: high dose.